Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 24, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically detailing activities related to the SmithKline Beecham Employee Benefit Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine share sales and transfers executed by the Trust on behalf of employee investment plan participants between May 16 and May 18, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance notification regarding specific share transactions under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- The SmithKline Beecham Employee Benefit Trust sold a total of 3,559 Ordinary shares on behalf of participants in the Annual Investment Plan and Bonus Investment Plan between May 16 and May 18, 2006.
- Share sale prices ranged from GBP15.05 to GBP15.41 per share during the reporting window.
- A total of 4,693 Ordinary shares were transferred from the Trust to participants in the Annual Investment Plan and Bonus Investment Plan during the same period.
- Director Mr. J Heslop holds an interest in the shares held by the Trust as a potential beneficiary, consistent with other non-US employees.
- The filing does not disclose any financial results or strategic updates for the company.